Janney Montgomery Scott LLC Lowers Position in GSK plc (NYSE:GSK)

Janney Montgomery Scott LLC decreased its stake in shares of GSK plc (NYSE:GSK) by 5.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 294,806 shares of the pharmaceutical company’s stock after selling 16,256 shares during the period. Janney Montgomery Scott LLC’s holdings in GSK were worth $12,052,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of GSK. Eastern Bank bought a new position in shares of GSK during the third quarter valued at about $26,000. Concord Wealth Partners increased its stake in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of GSK during the 2nd quarter worth approximately $37,000. Fortitude Family Office LLC purchased a new position in shares of GSK in the 3rd quarter worth approximately $42,000. Finally, PrairieView Partners LLC bought a new position in shares of GSK in the second quarter valued at approximately $47,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 10.00% of the company’s stock.

GSK Trading Down 3.0 %

Shares of GSK opened at $35.90 on Thursday. GSK plc has a fifty-two week low of $33.89 and a fifty-two week high of $45.92. The business has a 50-day moving average of $40.25 and a 200 day moving average of $40.97. The firm has a market cap of $74.39 billion, a P/E ratio of 23.31, a price-to-earnings-growth ratio of 1.42 and a beta of 0.66. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.38%. GSK’s dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analyst Weigh In

GSK has been the topic of several research analyst reports. Barclays raised GSK to a “hold” rating in a research report on Tuesday, August 27th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.